NVO
$36.53-0.55 (-1.48%)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationa...
Recent News
Hims & Hers (HIMS) Tumbles 8.86% on Market Bloodbath, Profit-Taking
Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stock Market Casualties You Can’t Ignore Today. Hims & Hers fell by 8.86 percent on Friday to close at $22.02 apiece, as investors unloaded positions amid a combination of market pessimism and profit-taking, having soared by as much as 88 percent already this month. […]
Beijing courts Eli Lilly as weight-loss drug race drives $3bn China commitment
Investing.com -- Eli Lilly and Company (NYSE:LLY) is deepening its footprint in the world’s second-largest economy, with Chinese Commerce Minister Wang Wentao expressing hope that the pharmaceutical giant will "deepen its commitment" and pursue more aggressive growth targets.
Does Hims & Hers (HIMS) Novo Nordisk Deal Quietly Redraw Its Risk Reward Profile?
Earlier in March 2026, Novo Nordisk agreed to resume selling its weight-loss drugs through the Hims & Hers Health platform, ending a public legal conflict over copycat medications and restoring a commercial relationship in one of healthcare’s most competitive categories. Days later, Hims & Hers appointed veteran communicator Kathryn Beiser as Chief Communications Officer, underscoring the company’s focus on strengthening its brand and explaining its broader telehealth ambitions to...
Why The Hims & Hers Health (HIMS) Story Is Resetting After Novo Deal And New Guidance
The modeled fair value for Hims & Hers Health has been revised from about US$44.36 to around US$23.69, a reset of roughly 47% in the price target framework. This shift aligns with Street commentary that balances enthusiasm around the renewed Novo Nordisk GLP-1 agreement with concerns related to recent results, 2026 guidance, legal and regulatory risk, and execution on new offerings. As you read on, you will see how these factors shape the evolving analyst narrative and what to watch...
Rhythm Grabs A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'
Rhythm Pharmaceuticals stock ultimately closed down Friday, though the FDA signed off on its drug, Imcivree, for a genetic form of obesity.